|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
113,340,000 |
Market
Cap: |
128.07(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$0.6758 - $2.77 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Karyopharm Therapeutics is a pharmaceutical company focused on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Co.'s main asset, XPOVIO® (selinexor), a Selective Inhibitors of Nuclear Export compound, is indicated for use in adult patients with multiple myeloma who have received at least one prior therapy; adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
41,140 |
41,140 |
Total Buy Value |
$0 |
$0 |
$49,985 |
$49,985 |
Total People Bought |
0 |
0 |
1 |
1 |
Total Buy Transactions |
0 |
0 |
1 |
1 |
Total Shares Sold |
255,827 |
267,169 |
308,707 |
975,987 |
Total Sell Value |
$306,355 |
$315,908 |
$380,503 |
$4,268,294 |
Total People Sold |
6 |
6 |
6 |
8 |
Total Sell Transactions |
19 |
22 |
33 |
58 |
End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Rangwala Reshma |
EVP & Chief Medical Officer |
|
2024-04-22 |
4 |
S |
$1.17 |
$7,943 |
D/D |
(6,789) |
342,931 |
|
4% |
|
Paulson Richard A. |
President and CEO |
|
2024-04-04 |
4 |
S |
$1.29 |
$4,596 |
D/D |
(3,563) |
1,157,273 |
|
19% |
|
Paulson Richard A. |
President and CEO |
|
2024-03-05 |
4 |
S |
$1.30 |
$4,645 |
D/D |
(3,573) |
1,160,836 |
|
13% |
|
Poulton Stuart |
EVP, Chief Development Officer |
|
2024-03-01 |
4 |
S |
$1.20 |
$7,386 |
D/D |
(6,155) |
329,511 |
|
9% |
|
Paulson Richard A. |
President and CEO |
|
2024-03-01 |
4 |
S |
$1.20 |
$23,249 |
D/D |
(19,374) |
1,164,409 |
|
9% |
|
Cheng Sohanya Roshan |
EVP & Chief Commercial Officer |
|
2024-03-01 |
4 |
S |
$1.20 |
$6,131 |
D/D |
(5,109) |
393,509 |
|
9% |
|
Mason Michael |
EVP, CFO & Treasurer |
|
2024-03-01 |
4 |
S |
$1.20 |
$7,394 |
D/D |
(6,162) |
398,756 |
|
9% |
|
Rangwala Reshma |
EVP & Chief Medical Officer |
|
2024-03-01 |
4 |
S |
$1.20 |
$7,163 |
D/D |
(5,969) |
349,720 |
|
9% |
|
Mano Michael |
SVP, General Counsel&Secretary |
|
2024-03-01 |
4 |
S |
$1.20 |
$4,291 |
D/D |
(3,576) |
277,852 |
|
9% |
|
Poulton Stuart |
EVP, Chief Development Officer |
|
2024-02-29 |
4 |
S |
$1.17 |
$19,084 |
D/D |
(16,311) |
335,666 |
|
7% |
|
Paulson Richard A. |
President and CEO |
|
2024-02-29 |
4 |
S |
$1.17 |
$94,150 |
D/D |
(80,470) |
1,183,783 |
|
7% |
|
Cheng Sohanya Roshan |
EVP & Chief Commercial Officer |
|
2024-02-29 |
4 |
S |
$1.17 |
$25,553 |
D/D |
(21,840) |
398,618 |
|
7% |
|
Mason Michael |
EVP, CFO & Treasurer |
|
2024-02-29 |
4 |
S |
$1.17 |
$32,394 |
D/D |
(27,687) |
404,918 |
|
7% |
|
Rangwala Reshma |
EVP & Chief Medical Officer |
|
2024-02-29 |
4 |
S |
$1.17 |
$18,330 |
D/D |
(15,667) |
355,689 |
|
7% |
|
Mano Michael |
SVP, General Counsel&Secretary |
|
2024-02-29 |
4 |
S |
$1.17 |
$19,858 |
D/D |
(16,973) |
281,428 |
|
7% |
|
Rangwala Reshma |
EVP & Chief Medical Officer |
|
2024-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
198,959 |
371,356 |
|
- |
|
Mano Michael |
SVP, General Counsel&Secretary |
|
2024-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
147,000 |
298,401 |
|
- |
|
Poulton Stuart |
EVP, Chief Development Officer |
|
2024-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
188,205 |
351,977 |
|
- |
|
Cheng Sohanya Roshan |
EVP & Chief Commercial Officer |
|
2024-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
198,959 |
420,458 |
|
- |
|
Paulson Richard A. |
President and CEO |
|
2024-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
442,800 |
1,264,253 |
|
- |
|
Mason Michael |
EVP, CFO & Treasurer |
|
2024-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
188,205 |
432,605 |
|
- |
|
Mason Michael |
EVP, CFO & Treasurer |
|
2024-02-27 |
4 |
S |
$1.32 |
$3,369 |
D/D |
(2,545) |
244,400 |
|
23% |
|
Poulton Stuart |
EVP, Chief Development Officer |
|
2024-02-15 |
4 |
S |
$1.33 |
$7,783 |
D/D |
(5,847) |
163,772 |
|
17% |
|
Mason Michael |
EVP, CFO & Treasurer |
|
2024-02-06 |
4 |
S |
$1.59 |
$6,671 |
D/D |
(4,205) |
246,945 |
|
35% |
|
Paulson Richard A. |
President and CEO |
|
2024-02-06 |
4 |
S |
$1.59 |
$6,365 |
D/D |
(4,012) |
821,453 |
|
35% |
|
85 Records found
|
|
Page 1 of 4 |
|
|